WA biotech duo takes aim at diabetes beyond Ozempic

A Western Australian biotechnology duo, comprising ProGenis and Syngenis Laboratories, is currently developing RNA-based therapies aimed at the next frontier of diabetes medicine. This collaboration seeks to advance treatments beyond the current standards set by medications like Ozempic, focusing on the potential of RNA technology to address metabolic health issues and provide new options for patients. The work represents a significant shift in how researchers approach the treatment of chronic conditions like diabetes.^[1][2][3]

Alongside their research and development work, the two companies are also building Australia’s first dedicated RNA facility. This project marks a significant development for the nation's medical infrastructure, as it will provide the necessary facilities to manufacture RNA-based treatments locally. The establishment of this facility is expected to bolster the domestic biotech sector and reduce reliance on international manufacturing for advanced RNA medicines.^[1][2][3]

By focusing on these advanced therapies and the construction of a specialized manufacturing site, ProGenis and Syngenis Laboratories are positioning Western Australia as a key player in the evolving field of RNA medicine. The initiative represents a concerted effort to expand the country's capabilities in treating diabetes through innovative biotechnological approaches, ensuring that Australia remains competitive in the global race for next-generation medical solutions.^[1][2][3]